Pfizer acquired the candidate following a bidding war with obesity giant Novo Nordisk for Metsera.

Roche reported positive Phase II topline data showing that its once-weekly dual glucagon-like peptide-1 and glucose-dependent ...

Amgen Inc (NASDAQ:AMGN) announced on Monday the full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate ...

Altimmune, Inc. closed a $75 million direct offering to fund Phase 3 pemvidutide trials for MASH. Learn more about ALT stock ...

--Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone-- --Based on Phase 2b QUALITY trial ...

Veradermics Completes Enrollment in its Phase 2/3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss, Advancing Development of the Potential First-Ever Extended-Release Oral Minoxidil ...

Roche said the Phase II results help build the case for advancing CT-388 into late-stage testing, which is set to get underway this quarter.

ZHENJIANG, China--(BUSINESS WIRE)--At 10:16 on January 17, State Grid Zhenjiang Power Supply Company successfully resolved a phase loss fault between Poles 17 and 18 on the 10 kV Antou 292 line of the ...

Biomed Industries, Inc. Announces Two NA-931 Phase 3 Trials, Targeting Durable Weight Loss & Lean-Mass Preservation at JP Morgan Week 2026 Advancing NA-931, the first oral quadruple receptor ...

Neuphoria Therapeutics Inc.’s phase III study of social anxiety disorder has missed its primary and secondary endpoints, prompting the company to stop the program’s development. Neuphoria also is ...

In January 2025, the Company announced positive topline results from the Phase 2b QUALITY clinical study, which is a multicenter, double-blind, placebo-controlled, randomized, dose-finding clinical ...